Parker Institute for Cancer Immunotherapy

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Parker Institute for Cancer Immunotherapy sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).

5 total trials none currently recruiting 5 completed early-phase tilt upper quartile by trial count

Parker Institute for Cancer Immunotherapy: 5 sponsored US clinical trials, none currently recruiting.

Parker Institute for Cancer Immunotherapy sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Metastatic Melanoma, with 1 trials.

Upper-quartile sponsor footprint

Parker Institute for Cancer Immunotherapy sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

5 total, page 1 of 1

COMPLETED Phase 1

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

NCT03835533
COMPLETED Phase 1

Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention

NCT03817125
COMPLETED Phase 2

Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer

NCT03651271
COMPLETED Phase 1

Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

NCT03214250
COMPLETED Phase 2

Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy

NCT02731729

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 2

Therapeutic Areas

Metastatic Melanoma 1
Melanoma 1

How the Parker Institute for Cancer Immunotherapy early-phase archive is shaped

5 indexed studies, none listed as recruiting (0% open); 5 completed (100%).

Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Metastatic Melanoma (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Parker Institute for Cancer Immunotherapy: archived-pipeline peers nationwide

Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Parker Institute for Cancer Immunotherapy sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20%25% Total trials Recruiting share Parker Institute for Cancer Immunotherapy4YouandMeAbbott Rapid DxAccess Business GroupAcera Surgical10xBio22nd Century Group23andMe3-C Institute for Social Development
Parker Institute for Cancer Immunotherapy sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Parker Institute for Cancer Immunotherapy sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 5 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Parker Institute for Cancer Immunotherapy page

5 registered trials is a research-attention snapshot, not an endorsement of Parker Institute for Cancer Immunotherapy or any single study.

  • None of Parker Institute for Cancer Immunotherapy's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Metastatic Melanoma is the condition Parker Institute for Cancer Immunotherapy studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Metastatic Melanoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Parker Institute for Cancer Immunotherapy pipeline card: 5 registered trials from official public datasets.Report a data error.